Malignant Melanoma - Pipeline Insight, 2020
This report can be delivered to the clients within 48-72 Hours
Malignant Melanoma Overview
'Malignant Melanoma Pipeline Insight, 2020' Report By DelveInsight Outlays Comprehensive Insights Of Present Clinical Development Scenario And Growth Prospects Across The Malignant Melanoma Market. A Detailed Picture Of The Malignant Melanoma Pipeline Landscape Is Provided, Which Includes The Disease Overview And Malignant Melanoma Treatment Guidelines.
The Assessment Part Of The Report Embraces In-Depth Malignant Melanoma Commercial Assessment And Clinical Assessment Of The Malignant Melanoma Pipeline Products From The Pre-Clinical Developmental Phase To The Marketed Phase.
In The Report, A Detailed Description Of The Drug Is Proffered Including Mechanism Of Action Of The Drug, Clinical Studies, NDA Approvals (If Any), And Product Development Activities Comprising The Technology, Malignant Melanoma Collaborations, Licensing, Mergers And Acquisition, Funding, Designations, And Other Product-Related Details.
Malignant Melanoma Of Pipeline Development Activities
The Report Provides Insights Into:
SCOPE OF THE REPORT
Malignant Melanoma Overview
'Malignant Melanoma Pipeline Insight, 2020' Report By DelveInsight Outlays Comprehensive Insights Of Present Clinical Development Scenario And Growth Prospects Across The Malignant Melanoma Market. A Detailed Picture Of The Malignant Melanoma Pipeline Landscape Is Provided, Which Includes The Disease Overview And Malignant Melanoma Treatment Guidelines.
The Assessment Part Of The Report Embraces In-Depth Malignant Melanoma Commercial Assessment And Clinical Assessment Of The Malignant Melanoma Pipeline Products From The Pre-Clinical Developmental Phase To The Marketed Phase.
In The Report, A Detailed Description Of The Drug Is Proffered Including Mechanism Of Action Of The Drug, Clinical Studies, NDA Approvals (If Any), And Product Development Activities Comprising The Technology, Malignant Melanoma Collaborations, Licensing, Mergers And Acquisition, Funding, Designations, And Other Product-Related Details.
Malignant Melanoma Of Pipeline Development Activities
The Report Provides Insights Into:
- All Of The Companies That Are Developing Therapies For The Treatment Of Malignant Melanoma With Aggregate Therapies Developed By Each Company For The Same.
- Different Therapeutic Candidates Segmented Into Early-Stage, Mid-Stage And Late Stage Of Development For The Malignant Melanoma Treatment.
- Malignant Melanoma Key Players Involved In Targeted Therapeutics Development With Respective Active And Inactive (Dormant Or Discontinued) Projects.
- Drugs Under Development Based On The Stage Of Development, Route Of Administration, Target Receptor, Monotherapy Or Combination Therapy, A Different Mechanism Of Action, And Molecular Type.
- Detailed Analysis Of Collaborations (Company-Company Collaborations And Company-Academia Collaborations), Licensing Agreement And Financing Details For Future Advancement Of Malignant Melanoma Market.
- The Report Is Built Using Data And Information Traced From The Researcher's Proprietary Databases, Company/University Websites, Clinical Trial Registries, Conferences, SEC Filings, Investor Presentations, And Featured Press Releases From Company/University Web Sites And Industry-Specific Third-Party Sources, Etc.
- In-Depth Malignant Melanoma Commercial Assessment Of Products
- Malignant Melanoma Clinical Assessment Of Products
SCOPE OF THE REPORT
- The Malignant Melanoma Report Provides An Overview Of Therapeutic Pipeline Activity And Therapeutic Assessment Of The Products By Development Stage, Product Type, Route Of Administration, Molecule Type, And MOA Type For Malignant Melanoma Across The Complete Product Development Cycle, Including All Clinical And Nonclinical Stages.
- It Comprises Of Detailed Profiles Of Malignant Melanoma Therapeutic Products With Key Coverage Of Developmental Activities, Including Technology, Collaborations, Licensing, Mergers And Acquisition, Funding, Designations And Other Product-Related Details
- Detailed Malignant Melanoma Research And Development Progress And Trial Details, Results Wherever Available, Are Also Included In The Pipeline Study.
- Coverage Of Dormant And Discontinued Pipeline Projects Along With The Reasons If Available Across Malignant Melanoma.
- A Better Understanding of Disease Pathogenesis Contributing To The Development Of Novel Therapeutics For Malignant Melanoma.
- In The Coming Years, The Malignant Melanoma Market Is Set To Change Due To The Rising Awareness Of The Disease, And Incremental Healthcare Spending Across The World; Which Would Expand The Size Of The Market To Enable The Drug Manufacturers To Penetrate More Into The Market.
- The Companies And Academics That Are Working To Assess Challenges And Seek Opportunities That Could Influence Malignant Melanoma R&D. The Therapies Under Development Are Focused On Novel Approaches To Treat/Improve The Disease Condition.
- A Detailed Portfolio of Major Pharma Players Who Are Involved In Fueling The Malignant Melanoma Treatment Market. Several Potential Therapies For Malignant Melanoma Are Under Investigation. With The Expected Launch Of These Emerging Therapies, It Is Expected That There Will Be A Significant Impact On The Malignant Melanoma Market Size In The Coming Years.
- Our In-Depth Analysis Of The Pipeline Assets (In Early-Stage, Mid-Stage And Late Stage Of Development For The Treatment Of Malignant Melanoma ) Includes Therapeutic Assessment And Comparative Analysis. This Will Support The Clients In The Decision-Making Process Regarding Their Therapeutic Portfolio By Identifying The Overall Scenario Of The Research And Development Activities.
- What Are The Current Options For Malignant Melanoma Treatment?
- How Many Companies Are Developing Therapies For The Treatment Of Malignant Melanoma?
- What Are The Principal Therapies Developed By These Companies In The Industry?
- How Many Therapies Are Developed By Each Company For The Treatment Of Malignant Melanoma?
- How Many Malignant Melanoma Emerging Therapies Are In Early-Stage, Mid-Stage, And Late Stage Of Development For The Treatment Of Malignant Melanoma?
- Out Of Total Pipeline Products, How Many Therapies Are Given As A Monotherapy And In Combination With Other Therapies?
- What Are The Key Collaborations (Industry-Industry, Industry-Academia), Mergers And Acquisitions, And Major Licensing Activities That Will Impact Malignant Melanoma Market?
- Which Are The Dormant And Discontinued Products And The Reasons For The Same?
- What Is The Unmet Need For Current Therapies For The Treatment Of Malignant Melanoma?
- What Are The Recent Novel Therapies, Targets, Mechanisms Of Action And Technologies Developed To Overcome The Limitation Of Existing Malignant Melanoma Therapies?
- What Are The Clinical Studies Going On For Malignant Melanoma And Their Status?
- What Are The Results Of The Clinical Studies And Their Safety And Efficacy?
- What Are The Key Designations That Have Been Granted For The Emerging Therapies For Malignant Melanoma?
- How Many Patents Are Granted And Pending For The Emerging Therapies For The Treatment Of Malignant Melanoma?
1. REPORT INTRODUCTION
2. MALIGNANT MELANOMA
2.1. Overview
2.2. History
2.3. Malignant Melanoma Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Malignant Melanoma Diagnosis
2.6.1. Diagnostic Guidelines
3. MALIGNANT MELANOMA CURRENT TREATMENT PATTERNS
3.1. Malignant Melanoma Treatment Guidelines
4. MALIGNANT MELANOMA - DELVEINSIGHT'S ANALYTICAL PERSPECTIVE
4.1. In-depth Commercial Assessment
4.1.1. Malignant Melanoma companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Malignant Melanoma Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Malignant Melanoma Acquisition Analysis
5. THERAPEUTIC ASSESSMENT
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. MALIGNANT MELANOMA LATE STAGE PRODUCTS (PHASE-III)
7. MALIGNANT MELANOMA MID STAGE PRODUCTS (PHASE-II)
8. EARLY STAGE PRODUCTS (PHASE-I)
9. PRE-CLINICAL PRODUCTS AND DISCOVERY STAGE PRODUCTS
10. INACTIVE PRODUCTS
11. DORMANT PRODUCTS
12. MALIGNANT MELANOMA DISCONTINUED PRODUCTS
13. MALIGNANT MELANOMA PRODUCT PROFILES
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report?
14. MALIGNANT MELANOMA KEY COMPANIES
15. MALIGNANT MELANOMA KEY PRODUCTS
16. DORMANT AND DISCONTINUED PRODUCTS
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. MALIGNANT MELANOMA UNMET NEEDS
18. MALIGNANT MELANOMA FUTURE PERSPECTIVES
19. MALIGNANT MELANOMA ANALYST REVIEW
20. APPENDIX
21. REPORT METHODOLOGY
21.1. Secondary Research
21.2. Expert Panel Validation
2. MALIGNANT MELANOMA
2.1. Overview
2.2. History
2.3. Malignant Melanoma Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Malignant Melanoma Diagnosis
2.6.1. Diagnostic Guidelines
3. MALIGNANT MELANOMA CURRENT TREATMENT PATTERNS
3.1. Malignant Melanoma Treatment Guidelines
4. MALIGNANT MELANOMA - DELVEINSIGHT'S ANALYTICAL PERSPECTIVE
4.1. In-depth Commercial Assessment
4.1.1. Malignant Melanoma companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Malignant Melanoma Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Malignant Melanoma Acquisition Analysis
5. THERAPEUTIC ASSESSMENT
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. MALIGNANT MELANOMA LATE STAGE PRODUCTS (PHASE-III)
7. MALIGNANT MELANOMA MID STAGE PRODUCTS (PHASE-II)
8. EARLY STAGE PRODUCTS (PHASE-I)
9. PRE-CLINICAL PRODUCTS AND DISCOVERY STAGE PRODUCTS
10. INACTIVE PRODUCTS
11. DORMANT PRODUCTS
12. MALIGNANT MELANOMA DISCONTINUED PRODUCTS
13. MALIGNANT MELANOMA PRODUCT PROFILES
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report?
14. MALIGNANT MELANOMA KEY COMPANIES
15. MALIGNANT MELANOMA KEY PRODUCTS
16. DORMANT AND DISCONTINUED PRODUCTS
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. MALIGNANT MELANOMA UNMET NEEDS
18. MALIGNANT MELANOMA FUTURE PERSPECTIVES
19. MALIGNANT MELANOMA ANALYST REVIEW
20. APPENDIX
21. REPORT METHODOLOGY
21.1. Secondary Research
21.2. Expert Panel Validation
LIST OF TABLES
Table 1: Malignant Melanoma Diagnostic Guidelines
Table 2: Malignant Melanoma Treatment Guidelines
Table 3: Assessment Summary
Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5: Malignant Melanoma Acquisition Analysis
Table 6: Assessment by Phase of Development
Table 7: Assessment by Product Type (Mono / Combination)
Table 8: Assessment by Stage and Product Type
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Assessment by MOA
Table 14: Assessment by Stage and MOA
Table 15: Assessment by Target
Table 16: Assessment by Stage and Target
Table 17: Malignant Melanoma Late Stage Products (Phase-III)
Table 18: Malignant Melanoma Mid Stage Products (Phase-II)
Table 19: Malignant Melanoma Early Stage Products (Phase-I)
Table 20: Pre-clinical and Discovery Stage Products
Table 21: Inactive Products
Table 22: Dormant Products
Table 23: Discontinued Products
Table 1: Malignant Melanoma Diagnostic Guidelines
Table 2: Malignant Melanoma Treatment Guidelines
Table 3: Assessment Summary
Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5: Malignant Melanoma Acquisition Analysis
Table 6: Assessment by Phase of Development
Table 7: Assessment by Product Type (Mono / Combination)
Table 8: Assessment by Stage and Product Type
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Assessment by MOA
Table 14: Assessment by Stage and MOA
Table 15: Assessment by Target
Table 16: Assessment by Stage and Target
Table 17: Malignant Melanoma Late Stage Products (Phase-III)
Table 18: Malignant Melanoma Mid Stage Products (Phase-II)
Table 19: Malignant Melanoma Early Stage Products (Phase-I)
Table 20: Pre-clinical and Discovery Stage Products
Table 21: Inactive Products
Table 22: Dormant Products
Table 23: Discontinued Products
LIST OF FIGURES
Figure 1: Disease Overview
Figure 2: History
Figure 3: Symptoms
Figure 4: Causes
Figure 5: Pathophysiology
Figure 6: Diagnostic Guidelines
Figure 7: Treatment Guidelines
Figure 8: Malignant Melanoma companies collaborations, Licensing, Acquisition -Deal Value Trends
Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10: Malignant Melanoma Acquisition Analysis
Figure 11: Assessment by Phase of Development
Figure 12: Assessment by Product Type (Mono / Combination)
Figure 13: Assessment by Stage and Product Type
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Assessment by MOA
Figure 19: Assessment by Stage and MOA
Figure 20: Late Stage Products (Phase-III)
Figure 21: Mid Stage Products (Phase-II)
Figure 22: Early Stage Products (Phase-I)
Figure 23: Pre-clinical and Discovery Stage Products
Figure 24: Inactive Products
Figure 25: Dormant Products
Figure 26: Discontinued Products
Figure 27: Unmet Needs
Figure 1: Disease Overview
Figure 2: History
Figure 3: Symptoms
Figure 4: Causes
Figure 5: Pathophysiology
Figure 6: Diagnostic Guidelines
Figure 7: Treatment Guidelines
Figure 8: Malignant Melanoma companies collaborations, Licensing, Acquisition -Deal Value Trends
Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10: Malignant Melanoma Acquisition Analysis
Figure 11: Assessment by Phase of Development
Figure 12: Assessment by Product Type (Mono / Combination)
Figure 13: Assessment by Stage and Product Type
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Assessment by MOA
Figure 19: Assessment by Stage and MOA
Figure 20: Late Stage Products (Phase-III)
Figure 21: Mid Stage Products (Phase-II)
Figure 22: Early Stage Products (Phase-I)
Figure 23: Pre-clinical and Discovery Stage Products
Figure 24: Inactive Products
Figure 25: Dormant Products
Figure 26: Discontinued Products
Figure 27: Unmet Needs
